Blood stage malaria vaccine
US9539316B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | May 28, 2012 |
| Grant date | Jan 10, 2017 |
| Priority date | — |
| Expiry date | Jun 30, 2032 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An immunogenic composition for use as a blood-stage malaria vaccine, a method of producing the immunogenic composition and a method of treatment of malaria are provided. The immunogenic composition includes isolated or purified merozoites, or red blood cells infected with merozoites, treated with centanamycin or tafuramycin A. The immunogenic composition does not include an adjuvant. A single dose of the immunogenic composition is sufficient to protect an animal against subsequent malaria infection by the same isolate, strain or species of Plasmodium used in the immunogenic composition, or by one or more heterologous isolates, strains or species of Plasmodium.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.